Panacea Biotec Wins ₹127.2 Crore bOPV Supply Order; Stock Up More Than 1%

New Delhi, October 9, 2025: Panacea Biotec Ltd (NSE: PANACEABIO; BSE: 531349) shares surged more than 1%. This was after the company informed that the Central Medical Services Society (CMSS), which is under the Ministry of Health and Family Welfare, has approved its tender for the supply of bivalent oral polio vaccine (bOPV) at ₹127.2 crore. The supply shall be carried out in several tranches within a span of 90 to 480 days from the date of the Letter of Acceptance on October 8, 2025.

Established in 1984 and listed since 1996, Panacea Biotec is a research-based biotechnology and pharmaceutical firm dealing in vaccines, biosimilars, and pharmaceutical formulations. The firm is a major contributor to India’s healthcare and preventive medicine industry.

Contract Details

The order, which is all domestic in nature, has no connection with any group or promoter interest and contains no related-party transactions. Panacea Biotec shall follow stringent quality compliance during the supply duration with regular deliveries as per the agreed timeframe.

Market Reaction

Post the announcement, Panacea Biotec shares appreciated 1.22% to ₹436.40 at 2:19 pm IST. The stock hit an intraday high of ₹445.05 and an intraday low of ₹428.05, with 1.42 lakh shares changing hands. The 52-week range of the stock is ₹271.20 to ₹581.90, and the market capitalization of the company is ₹2,662.88 crore with a P/E of 237.48.

Management Commentary

Vinod Goel, Group CFO & Head Legal & Company Secretary, said that the firm is dedicated to completing the order as per schedule while upholding quality standards during the supply duration.

REF: https://nsearchives.nseindia.com/corporate/PANACEABIO_09102025121439_IntimationforacceptanceofofferforbOPV.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations